Finding Responders: The Next Phase of OA Biomarkers with Dr Virginia Kraus, Dr Peter Mesenbrink, and Dr Jamie Collins
Joint ActionShow Notes
Can identifying the right patients and the right endpoints transform how we test new osteoarthritis treatments? On this week's episode of Joint Action, we unpack what the FNIH Biomarkers Consortium has learned so far, and how their latest phase aims to deliver biomarkers that can make disease-modifying OA drug trials smaller, faster, and more likely to succeed.
Dr. Virginia Byers Kraus is a Professor of Medicine, Pathology, and Orthopaedic Surgery at Duke University School of Medicine. A rheumatologist and translational scientist, her research focuses on osteoarthritis and biomarker development as part of the international FNIH Biomarkers Consortium.
Peter G. Mesenbrink, Ph.D., is Executive Director of Biostatistics at Novartis and industry co-chair of the FNIH Biomarkers Consortium. With expertise in adaptive trial design, surrogate endpoint development, and data sharing policy, he is a frequent collaborator across industry, regulatory, and academic communities.
Dr. Jamie Collins is a biostatistician at Brigham and Women's Hospital and Associate Professor of Orthopaedic Surgery at Harvard Medical School. As lead statistician for the FNIH OA Biomarkers Consortium, her research focuses on strengthening osteoarthritis clinical trials through innovative trial design and prognostic enrichment.
RESOURCES FNIH: Treatment Response Biomarkers for Disease Modifying Osteoarthritis Drugs (DMOADs)
CONNECT WITH US Naia Health: https://www.naiahealth.com.au/st-leonards-hub Join one of our trials https://www.osteoarthritisresearch.com.au/current-trials Instagram: @ProfDavidHunter Twitter: @ProfDavidHunter @jointactionorg Email: [email protected] Website: www.jointaction.info/podcast
If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.
More from Joint Action
On this special World Arthritis Day episode of Joint Action, we are bringing together some of the most moving moments from our patient stories series, where real people share what it is like to live with osteoarthritis, and more importantly, what they did about it.
Do supplements really help with osteoarthritis, or are we wasting our money? On this week's episode of Joint Action, Associate Professor Joanna Harnett and Dr Jocelyn Bowden join Professor David Hunter to cut through the noise on complementary medicines, exploring what the evidence actually shows and how to make informed decisions about supplement use for osteoarthritis.
What does it really mean to live with hand osteoarthritis, and how do you stay active and engaged in life when your hands are constantly painful? On this week's episode of Joint Action, Giovanna Lever joins Professor David Hunter to share her personal journey living with hand osteoarthritis, diagnosed at 45 after years of struggling with pain, and what it has meant for her work, travel, and family life.
Is platelet-rich-plasma (PRP) a game changer for osteoarthritis, or is the evidence still catching up with the hype? On this week's episode of Joint Action, Dr Hamish Osborne joins Professor David Hunter to cut through the noise on PRP exploring what the research currently shows, where the gaps in evidence lie, and how patients and clinicians can navigate the decision together.
Do your knees crack, pop, or creak when you move? On this week's episode of Joint Action, Associate Professor Danilo De Oliveira Silva joins Professor David Hunter to explain what those sounds actually mean, whether they are something to worry about, and what the research tells us about the relationship between noisy knees and osteoarthritis.